HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gabriel N Hortobagyi Selected Research

Neoadjuvant Therapy

5/2023Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial.
1/2023Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer.
1/2022Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.
10/2021Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.
10/2019Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial.
2/2018Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer.
1/2018Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.
4/2017Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
7/2016The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.
10/2015Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Gabriel N Hortobagyi Research Topics

Disease

433Breast Neoplasms (Breast Cancer)
11/2023 - 01/2002
276Neoplasms (Cancer)
11/2023 - 01/2002
67Neoplasm Metastasis (Metastasis)
01/2024 - 06/2002
43Pathologic Complete Response
05/2023 - 06/2005
32Triple Negative Breast Neoplasms
01/2024 - 03/2008
22Disease Progression
12/2021 - 04/2002
16Inflammatory Breast Neoplasms
10/2021 - 01/2003
12Residual Neoplasm
01/2018 - 04/2004
11Circulating Neoplastic Cells
01/2023 - 03/2005
9Cardiotoxicity
10/2021 - 11/2002
8Neutropenia
01/2023 - 07/2003
7Peripheral Nervous System Diseases (PNS Diseases)
11/2023 - 11/2012
6Heart Failure
01/2023 - 11/2002
6Ovarian Neoplasms (Ovarian Cancer)
01/2019 - 11/2002
6Carcinogenesis
07/2014 - 03/2004
5Obesity
10/2021 - 09/2008
5Infections
05/2021 - 10/2002
5Noninfiltrating Intraductal Carcinoma (DCIS)
10/2014 - 06/2002
4Hypersensitivity (Allergy)
11/2023 - 05/2002
4Fatigue
01/2019 - 02/2004
4Febrile Neutropenia
01/2019 - 01/2003
4Pain (Aches)
01/2016 - 06/2002

Drug/Important Bio-Agent (IBA)

83Hormones (Hormone)IBA
01/2023 - 10/2002
71Estrogen ReceptorsIBA
10/2023 - 01/2002
49Doxorubicin (Adriamycin)FDA LinkGeneric
01/2023 - 01/2002
47AnthracyclinesIBA
09/2023 - 02/2002
45Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2022 - 01/2002
42Trastuzumab (Herceptin)FDA Link
12/2019 - 04/2002
40Paclitaxel (Taxol)FDA LinkGeneric
11/2023 - 05/2002
37Biomarkers (Surrogate Marker)IBA
01/2023 - 06/2002
36human ERBB2 proteinIBA
10/2023 - 01/2004
34Fluorouracil (Carac)FDA LinkGeneric
01/2019 - 01/2002
32Progesterone Receptors (Progesterone Receptor)IBA
10/2023 - 10/2002
32taxaneIBA
11/2018 - 02/2002
31Proteins (Proteins, Gene)FDA Link
09/2017 - 09/2003
26ErbB Receptors (EGF Receptor)IBA
12/2022 - 10/2002
19TamoxifenFDA LinkGeneric
01/2020 - 01/2002
19Docetaxel (Taxotere)FDA Link
04/2014 - 01/2002
18EverolimusFDA Link
01/2022 - 10/2007
17DNA (Deoxyribonucleic Acid)IBA
01/2019 - 03/2004
16Aromatase InhibitorsIBA
01/2019 - 03/2004
16Taxoids (Taxanes)IBA
10/2015 - 05/2002
15Estrogens (Estrogen)FDA Link
01/2020 - 07/2003
15exemestane (Aromasin)FDA Link
01/2019 - 03/2004
14Phosphotransferases (Kinase)IBA
01/2024 - 05/2003
13Messenger RNA (mRNA)IBA
01/2023 - 06/2005
12Diphosphonates (Bisphosphonates)IBA
05/2021 - 10/2003
12Epidermal Growth Factor (EGF)IBA
10/2020 - 10/2007
9Zoledronic Acid (Zometa)FDA Link
05/2021 - 01/2005
9Capecitabine (Xeloda)FDA Link
03/2012 - 09/2003
8Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2023 - 07/2015
8Anastrozole (Arimidex)FDA LinkGeneric
01/2022 - 06/2002
8Bevacizumab (Avastin)FDA Link
01/2018 - 10/2004
8Lapatinib (GW572016)FDA Link
07/2014 - 07/2008
7ribociclibIBA
01/2023 - 11/2016
7Biological FactorsIBA
12/2022 - 07/2016
7Monoclonal AntibodiesIBA
01/2022 - 06/2002
7Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2022 - 04/2004
7RNA (Ribonucleic Acid)IBA
10/2021 - 06/2003
7Immune Checkpoint InhibitorsIBA
01/2021 - 07/2017
7Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2019 - 08/2007
7Indicators and Reagents (Reagents)IBA
01/2019 - 11/2002
7Epirubicin (Ellence)FDA LinkGeneric
11/2015 - 06/2005
7Tyrosine Kinase InhibitorsIBA
07/2014 - 06/2003
6Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
01/2023 - 01/2013
6Letrozole (Femara)FDA LinkGeneric
10/2022 - 11/2016
6LigandsIBA
01/2021 - 12/2009
6ParaffinIBA
12/2019 - 04/2004
6Cyclin-Dependent Kinases (cdk Proteins)IBA
01/2019 - 10/2006
6Tumor Biomarkers (Tumor Markers)IBA
10/2014 - 10/2002
6Transcription Factors (Transcription Factor)IBA
02/2012 - 09/2003
5Phenobarbital (Luminal)FDA Link
11/2019 - 08/2005
5Metformin (Glucophage)FDA LinkGeneric
01/2019 - 07/2009
5Antineoplastic Agents (Antineoplastics)IBA
01/2019 - 01/2007
5ixabepilone (BMS 247550)FDA Link
10/2015 - 08/2007
5Granulocyte Colony-Stimulating Factor (G-CSF)IBA
03/2011 - 01/2002
5Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2011 - 06/2007
4SteroidsIBA
01/2024 - 10/2002
4EnzymesIBA
01/2023 - 04/2004
4PlatinumIBA
01/2023 - 05/2008
4Fulvestrant (Faslodex)FDA Link
01/2022 - 08/2012
4CytokinesIBA
01/2021 - 02/2004
4Methotrexate (Mexate)FDA LinkGeneric
01/2019 - 11/2003
4Tyrosine (L-Tyrosine)FDA Link
01/2019 - 08/2007
4Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
01/2019 - 01/2008
4TOR Serine-Threonine KinasesIBA
01/2019 - 02/2012
4GemcitabineFDA Link
01/2018 - 05/2002
4Cyclin EIBA
06/2017 - 11/2002
4Dasatinib (BMS 354825)FDA Link
12/2016 - 05/2010
4Selective Estrogen Receptor Modulators (SERM)IBA
01/2016 - 03/2004

Therapy/Procedure

191Therapeutics
10/2023 - 01/2002
163Drug Therapy (Chemotherapy)
11/2023 - 01/2002
80Neoadjuvant Therapy
05/2023 - 01/2002
33Radiotherapy
01/2023 - 06/2002
31Adjuvant Chemotherapy
12/2019 - 01/2002
15Mastectomy (Mammectomy)
06/2014 - 01/2002
11Segmental Mastectomy (Lumpectomy)
10/2021 - 07/2002
9Aftercare (After-Treatment)
01/2023 - 07/2002
4Immunotherapy
01/2023 - 01/2019
4Precision Medicine
01/2021 - 11/2006